Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Scientific Reports|February 5, 2026
Mechanistic insights into postoperative delirium using untargeted high-throughput proteomics in elderly patients - a case-control studyMario Lamping, Maria Heinrich, Vadim Farztdinov, et al.
JCO Precision Oncology|February 9, 2022
Comparison of Treatment Recommendations by Molecular Tumor Boards WorldwideDamian T Rieke, Mario Lamping, Marissa Schuh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 5, 2020
Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine?Theresia Pichler, Amy Rohrmoser, Anne Letsch, et al.
JCO Precision Oncology|September 11, 2020
Comparative Analysis of Public Knowledge Bases for Precision OncologySteffen Pallarz, Manuela Benary, Mario Lamping, et al.
BMC Bioinformatics|August 18, 2019
VIST - a Variant-Information Search Tool for precision oncologyJurica Ševa, David Luis Wiegandt, Julian Götze, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2023
Tumour mutational burden and survival with molecularly matched therapyTill de Bortoli, Manuela Benary, Peter Horak, et al.
BMC Medicine|October 24, 2022
Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boardsDamian T Rieke, Till de Bortoli, Peter Horak, et al.
JAMIA Open|April 26, 2021
Annotation and initial evaluation of a large annotated German oncological corpusMadeleine Kittner, Mario Lamping, Damian T Rieke, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2020
Support of a molecular tumour board by an evidence-based decision management system for precision oncologyMario Lamping, Manuela Benary, Serge Leyvraz, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2022
Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility studySerge Leyvraz, Frank Konietschke, Caroline Peuker, et al.
Pageof 2